| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.971 | 0.002 | 0.971 | Aldehyde oxidase inhibitor | 0.826 0.004 DBMET02524 0.765 0.005 DBMET02527 0.779 0.005 DBMET02522 | ||
| 0.916 | 0.001 | 0.916 | Estrogen receptor alpha antagonist | 0.738 0.002 DBMET02524 0.633 0.003 DBMET02527 0.527 0.003 DBMET02522 | ||
| 0.847 | 0.002 | 0.847 | Estrogen receptor beta antagonist | 0.615 0.003 DBMET02524 0.564 0.003 DBMET02527 0.594 0.003 DBMET02522 | ||
| 0.842 | 0.002 | 0.842 | Estrogen antagonist | 0.625 0.003 DBMET02524 0.559 0.004 DBMET02527 0.578 0.004 DBMET02522 | ||
| 0.693 | 0.008 | 0.78 | Cholesterol antagonist | 0.779 0.004 DBMET02524 0.773 0.005 DBMET02527 0.78 0.004 DBMET02522 | DBMET02522 | |
| 0.574 | 0.003 | 0.574 | Estrogen agonist | 0.375 0.004 DBMET02524 0.323 0.005 DBMET02527 0.355 0.004 DBMET02522 | ||
| 0.483 | 0.018 | 0.483 | Vasodilator, coronary | 0.391 0.038 DBMET02524 0.397 0.036 DBMET02527 0.444 0.024 DBMET02522 | ||
| 0.483 | 0.035 | 0.483 | Calcium channel L-type activator | 0.416 0.071 DBMET02524 0.39 0.088 DBMET02527 0.431 0.061 DBMET02522 | ||
| 0.452 | 0.011 | 0.452 | Calcium channel activator | 0.371 0.037 DBMET02524 0.383 0.032 DBMET02527 0.38 0.033 DBMET02522 | ||
| 0.46 | 0.078 | 0.46 | Caspase 9 stimulant | 0.267 0.233 DBMET02522 | ||
| 0.416 | 0.034 | 0.416 | Lipoxygenase inhibitor | 0.19 0.151 DBMET02524 | ||
| 0.39 | 0.027 | 0.396 | Hypolipemic | 0.365 0.032 DBMET02524 0.375 0.03 DBMET02527 0.396 0.026 DBMET02522 | DBMET02522 | |
| 0.349 | 0.053 | 0.349 | Spasmolytic | |||
| 0.284 | 0.006 | 0.284 | Dopamine D1 antagonist | |||
| 0.288 | 0.015 | 0.288 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.233 | 0.004 | 0.233 | Estrogen receptor alpha agonist | 0.106 0.008 DBMET02524 0.082 0.011 DBMET02527 0.1 0.009 DBMET02522 | ||
| 0.296 | 0.091 | 0.384 | Antithrombotic | 0.377 0.056 DBMET02524 0.384 0.054 DBMET02527 0.359 0.061 DBMET02522 | DBMET02527 | |
| 0.208 | 0.004 | 0.208 | Estrogen receptor beta agonist | 0.116 0.01 DBMET02524 0.077 0.015 DBMET02527 0.111 0.01 DBMET02522 | ||
| 0.229 | 0.025 | 0.229 | Toll-Like receptor 9 antagonist | |||
| 0.223 | 0.031 | 0.223 | Tubulin antagonist | |||
| 0.261 | 0.075 | 0.261 | Cardiotonic | |||
| 0.184 | 0.004 | 0.184 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.067 0.009 DBMET02524 0.054 0.014 DBMET02527 0.063 0.01 DBMET02522 | ||
| 0.206 | 0.03 | 0.206 | Interleukin 1 antagonist | 0.146 0.06 DBMET02524 0.15 0.057 DBMET02527 0.128 0.078 DBMET02522 | ||
| 0.25 | 0.075 | 0.25 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.283 | 0.11 | 0.283 | Prostaglandin dehydrogenase inhibitor | |||
| 0.198 | 0.031 | 0.198 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.178 | 0.017 | 0.178 | Breast cancer-resistant protein inhibitor | 0.085 0.072 DBMET02522 | ||
| 0.207 | 0.051 | 0.207 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.161 | 0.005 | 0.161 | Estradiol 17 beta-dehydrogenase inhibitor | |||
| 0.17 | 0.018 | 0.17 | Multidrug resistance-associated protein 1 inhibitor | 0.1 0.079 DBMET02524 0.096 0.086 DBMET02527 0.106 0.068 DBMET02522 | ||
| 0.157 | 0.009 | 0.157 | Alpha tubulin antagonist | 0.056 0.034 DBMET02524 0.05 0.04 DBMET02527 0.056 0.034 DBMET02522 | ||
| 0.168 | 0.022 | 0.168 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.207 | 0.067 | 0.207 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.216 | 0.083 | 0.216 | Cyclic AMP phosphodiesterase inhibitor | 0.164 0.131 DBMET02524 0.164 0.129 DBMET02527 | ||
| 0.202 | 0.069 | 0.202 | Non-steroidal antiinflammatory agent | 0.172 0.093 DBMET02524 0.178 0.089 DBMET02527 0.171 0.095 DBMET02522 | ||
| 0.229 | 0.096 | 0.229 | Antioxidant | 0.203 0.111 DBMET02524 0.164 0.149 DBMET02527 0.201 0.113 DBMET02522 | ||
| 0.175 | 0.044 | 0.175 | Bone formation stimulant | 0.105 0.1 DBMET02524 | ||
| 0.197 | 0.077 | 0.197 | Insulin sensitizer | |||
| 0.124 | 0.005 | 0.124 | Phospholipase D inhibitor | 0.067 0.061 DBMET02524 0.073 0.046 DBMET02527 | ||
| 0.164 | 0.047 | 0.164 | Acetylcholinesterase inhibitor | |||
| 0.142 | 0.026 | 0.142 | Histamine H1 receptor antagonist | 0.071 0.068 DBMET02524 0.09 0.048 DBMET02527 | ||
| 0.213 | 0.101 | 0.336 | Hypoglycemic | 0.33 0.043 DBMET02524 0.321 0.046 DBMET02527 0.336 0.041 DBMET02522 | DBMET02522 | |
| 0.186 | 0.075 | 0.186 | P-glycoprotein inhibitor | 0.142 0.13 DBMET02524 0.143 0.128 DBMET02527 0.159 0.103 DBMET02522 | ||
| 0.148 | 0.039 | 0.148 | Alpha 2b adrenoreceptor antagonist | |||
| 0.141 | 0.037 | 0.141 | Nav1.1 sodium channel blocker | |||
| 0.136 | 0.032 | 0.136 | 5 Hydroxytryptamine 2A antagonist | |||
| 0.155 | 0.053 | 0.155 | MAP kinase kinase 4 inhibitor | |||
| 0.111 | 0.008 | 0.111 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.153 | 0.054 | 0.153 | c-Src kinase inhibitor | |||
| 0.173 | 0.074 | 0.173 | Tumour necrosis factor antagonist | |||
| 0.187 | 0.091 | 0.187 | Interleukin antagonist | 0.138 0.128 DBMET02524 | ||
| 0.163 | 0.067 | 0.163 | Cholinergic | |||
| 0.134 | 0.042 | 0.134 | Alpha adrenoreceptor antagonist | |||
| 0.106 | 0.017 | 0.106 | Dopamine uptake inhibitor | 0.057 0.041 DBMET02524 0.064 0.035 DBMET02527 | ||
| 0.093 | 0.006 | 0.093 | Leukotriene A4 hydrolase inhibitor | 0.07 0.011 DBMET02524 0.077 0.009 DBMET02527 0.056 0.017 DBMET02522 | ||
| 0.176 | 0.091 | 0.176 | Amyloid beta aggregation inhibitor | |||
| 0.116 | 0.032 | 0.116 | Histamine N-methyltransferase inhibitor | |||
| 0.129 | 0.045 | 0.129 | Protein kinase C gamma inhibitor | |||
| 0.127 | 0.045 | 0.127 | Alpha 2c adrenoreceptor antagonist | |||
| 0.227 | 0.147 | 0.293 | Interleukin 2 agonist | 0.293 0.079 DBMET02524 0.288 0.082 DBMET02527 0.276 0.092 DBMET02522 | DBMET02524 | |
| 0.117 | 0.038 | 0.117 | Alpha 1 adrenoreceptor antagonist | |||
| 0.109 | 0.032 | 0.109 | Alpha 1b adrenoreceptor antagonist | |||
| 0.083 | 0.011 | 0.083 | Thromboxane synthase inhibitor | |||
| 0.094 | 0.024 | 0.094 | Beta tubulin antagonist | |||
| 0.148 | 0.083 | 0.285 | Thrombolytic | 0.281 0.027 DBMET02524 0.285 0.026 DBMET02527 0.156 0.077 DBMET02522 | DBMET02527 | |
| 0.099 | 0.036 | 0.099 | Histamine H2 receptor antagonist | |||
| 0.205 | 0.146 | 0.205 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.141 | 0.083 | 0.141 | Acetylcholine M1 receptor antagonist | |||
| 0.134 | 0.08 | 0.134 | Lipid peroxidase inhibitor | |||
| 0.072 | 0.018 | 0.076 | Plasminogen activator inhibitor antagonist | 0.074 0.017 DBMET02524 0.076 0.016 DBMET02527 0.073 0.018 DBMET02522 | DBMET02527 | |
| 0.093 | 0.039 | 0.093 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.092 | 0.04 | 0.092 | Alpha 2a adrenoreceptor antagonist | |||
| 0.1 | 0.048 | 0.1 | Alpha 2 adrenoreceptor antagonist | |||
| 0.118 | 0.069 | 0.118 | Anesthetic local | |||
| 0.215 | 0.168 | 0.278 | Sodium/bile acid cotransporter inhibitor | 0.278 0.1 DBMET02524 0.26 0.118 DBMET02527 0.26 0.118 DBMET02522 | DBMET02524 | |
| 0.171 | 0.123 | 0.171 | Free radical scavenger | 0.154 0.14 DBMET02524 0.148 0.147 DBMET02522 | ||
| 0.184 | 0.137 | 0.184 | Superoxide dismutase inhibitor | |||
| 0.051 | 0.007 | 0.051 | Estradiol 17 beta-dehydrogenase 1 inhibitor | |||
| 0.099 | 0.056 | 0.099 | Antiadrenergic | |||
| 0.143 | 0.1 | 0.179 | Interleukin 6 antagonist | 0.179 0.055 DBMET02524 0.179 0.056 DBMET02527 | DBMET02527 | |
| 0.081 | 0.039 | 0.081 | Dopamine D2 antagonist | |||
| 0.057 | 0.015 | 0.057 | Geranyltranstransferase inhibitor | |||
| 0.134 | 0.092 | 0.134 | NOS3 expression enhancer | 0.123 0.109 DBMET02524 0.122 0.111 DBMET02522 | ||
| 0.07 | 0.029 | 0.07 | Protein kinase C eta inhibitor | |||
| 0.136 | 0.095 | 0.136 | Protein-tyrosine phosphatase inhibitor | 0.12 0.114 DBMET02524 0.124 0.109 DBMET02522 | ||
| 0.128 | 0.087 | 0.128 | Farnesoid X receptor antagonist | 0.123 0.096 DBMET02524 0.117 0.11 DBMET02522 | ||
| 0.11 | 0.071 | 0.11 | 5 Hydroxytryptamine antagonist | |||
| 0.079 | 0.041 | 0.079 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.095 | 0.057 | 0.095 | Adrenaline antagonist | |||
| 0.096 | 0.058 | 0.1 | Bile acid receptor antagonist | 0.099 0.05 DBMET02524 0.095 0.061 DBMET02527 0.1 0.05 DBMET02522 | DBMET02522 | |
| 0.099 | 0.063 | 0.099 | Butyrylcholinesterase inhibitor | |||
| 0.082 | 0.046 | 0.082 | Dopamine antagonist | |||
| 0.116 | 0.081 | 0.116 | DNA repair enzyme inhibitor | |||
| 0.094 | 0.06 | 0.094 | Antihistaminic | |||
| 0.136 | 0.105 | 0.136 | Arachidonic acid antagonist | |||
| 0.116 | 0.086 | 0.116 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | |||
| 0.166 | 0.138 | 0.184 | Tumour necrosis factor alpha release inhibitor | 0.183 0.124 DBMET02524 0.184 0.123 DBMET02527 | DBMET02527 | |
| 0.046 | 0.019 | 0.046 | GABA uptake inhibitor | 0.038 0.03 DBMET02527 | ||
| 0.127 | 0.101 | 0.127 | Src kinase inhibitor | |||
| 0.106 | 0.081 | 0.106 | Microtubule formation inhibitor | 0.099 0.093 DBMET02527 | ||
| 0.218 | 0.193 | 0.218 | 15-Lipoxygenase inhibitor | |||
| 0.158 | 0.134 | 0.158 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.1 | 0.076 | 0.1 | DOPA decarboxylase inhibitor | |||
| 0.042 | 0.018 | 0.042 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | |||
| 0.046 | 0.022 | 0.046 | Dopamine D3 agonist | |||
| 0.046 | 0.025 | 0.046 | DNA-dependent protein kinase inhibitor | |||
| 0.082 | 0.062 | 0.082 | Histamine antagonist | |||
| 0.047 | 0.027 | 0.047 | Dopamine D5 antagonist | |||
| 0.127 | 0.108 | 0.127 | Adenylate cyclase stimulant | |||
| 0.069 | 0.05 | 0.069 | Peroxisome proliferator-activated receptor gamma agonist | |||
| 0.05 | 0.032 | 0.05 | Peroxisome proliferator-activated receptor alpha agonist | |||
| 0.109 | 0.091 | 0.109 | Cyclooxygenase 1 inhibitor | |||
| 0.059 | 0.042 | 0.083 | Prostaglandin EP2 antagonist | 0.069 0.034 DBMET02524 0.074 0.03 DBMET02527 0.083 0.025 DBMET02522 | DBMET02522 | |
| 0.124 | 0.109 | 0.124 | Sigma receptor agonist | |||
| 0.037 | 0.022 | 0.037 | ATM kinase inhibitor | |||
| 0.103 | 0.088 | 0.103 | MAO inhibitor | |||
| 0.13 | 0.116 | 0.13 | Dual specificity phosphatase 3 inhibitor | |||
| 0.11 | 0.098 | 0.11 | Antibacterial (Helicobacter pylori) | |||
| 0.083 | 0.072 | 0.083 | Protein kinase C delta inhibitor | |||
| 0.033 | 0.023 | 0.033 | Protein kinase C beta I inhibitor | |||
| 0.088 | 0.078 | 0.088 | Interleukin 12 antagonist | |||
| 0.054 | 0.045 | 0.054 | Alpha 1d adrenoreceptor antagonist | |||
| 0.047 | 0.04 | 0.047 | Squalene epoxidase inhibitor | |||
| 0.14 | 0.132 | 0.14 | Antimitotic | |||
| 0.084 | 0.077 | 0.084 | MAO A inhibitor | |||
| 0.095 | 0.088 | 0.095 | Interleukin 1b antagonist | |||
| 0.056 | 0.05 | 0.056 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.015 | 0.01 | 0.015 | 4-Hydroxyphenylpyruvate dioxygenase inhibitor | |||
| 0.143 | 0.138 | 0.143 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.05 | 0.046 | 0.058 | Sphingosine 1-phosphate receptor 5 agonist | 0.055 0.034 DBMET02524 0.058 0.029 DBMET02527 0.056 0.032 DBMET02522 | DBMET02527 | |
| 0.03 | 0.027 | 0.03 | Peroxisome proliferator-activated receptor delta agonist | |||
| 0.18 | 0.177 | 0.18 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.205 | 0.269 | 0.422 | Cyclophilin D inhibitor | 0.415 0.083 DBMET02524 0.422 0.079 DBMET02527 0.396 0.093 DBMET02522 | DBMET02527 | |
| 0.079 | 0.188 | 0.143 | Anticoagulant | 0.135 0.094 DBMET02524 0.143 0.087 DBMET02527 | DBMET02527 | |
| 0.071 | 0.194 | 0.126 | Interleukin 4 antagonist | 0.126 0.077 DBMET02524 0.107 0.106 DBMET02527 | DBMET02524 | |
| 0.079 | 0.244 | 0.136 | Hepatoprotectant | 0.136 0.126 DBMET02522 | DBMET02522 | |
| 0.124 | 0.295 | 0.27 | Immunosuppressant | 0.237 0.159 DBMET02524 0.24 0.156 DBMET02527 0.27 0.135 DBMET02522 | DBMET02522 | |
| 0.015 | 0.26 | 0.123 | Selectin antagonist | 0.12 0.022 DBMET02524 0.123 0.022 DBMET02527 | DBMET02527 | |
| 0.006 | 0.271 | 0.056 | Prostaglandin D2 agonist | 0.056 0.006 DBMET02522 | DBMET02522 | |
| 0.003 | 0.295 | 0.015 | Prostacyclin agonist | 0.015 0.012 DBMET02522 | DBMET02522 | |
| 0.054 | 0.349 | 0.177 | Platelet antagonist | 0.166 0.129 DBMET02524 0.177 0.12 DBMET02527 | DBMET02527 | |
| 0.001 | 0.382 | 0.014 | Antibiotic Macrolide-like | 0.013 0.01 DBMET02524 0.014 0.01 DBMET02527 | DBMET02527 | |
| 0.017 | 0.417 | 0.275 | Glutamate receptor antagonist | 0.275 0.012 DBMET02522 | DBMET02522 | |
| 0.107 | 0.51 | 0.351 | Antiinflammatory | 0.351 0.172 DBMET02524 0.338 0.182 DBMET02527 | DBMET02524 | |
| 0.013 | 0.498 | 0.034 | Glutamate (mGluR8) antagonist | 0.034 0.031 DBMET02527 | DBMET02527 | |
| 0.004 | 0.511 | 0.596 | Glutamate (mGluR2) agonist | 0.596 0.003 DBMET02522 | DBMET02522 | |
| 0.006 | 0.517 | 0.603 | Glutamate (mGluR group II) agonist | 0.603 0.003 DBMET02522 | DBMET02522 | |
| 0.033 | 0.636 | 0.226 | Antibacterial | 0.226 0.2 DBMET02524 | DBMET02524 | |
| 0.005 | 0.647 | 0.445 | Glutamate (mGluR) agonist | 0.445 0.004 DBMET02522 | DBMET02522 | |
| 0.005 | 0.689 | 0.169 | Glutamate (mGluR) antagonist | 0.169 0.014 DBMET02522 | DBMET02522 | |
| 0.007 | 0.727 | 0.056 | Protein 50S ribosomal subunit inhibitor | 0.053 0.036 DBMET02524 0.056 0.034 DBMET02527 | DBMET02527 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |